RxDoctor Payments Data

Jose Rendon-Garcia, MD

Internal Medicine · Savannah, GANPI 1083650972

Payments from drug & device makers

$12,473in general payments, 2019–2025

Across 878 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$660
  • Amgen$637
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$12,447100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,473 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$81,055
Medicare patients
271
Services billed
1,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide170$186,566
FarxigaDapagliflozin Propanediol218$175,149
TrulicityDulaglutide69$88,002
OzempicSemaglutide76$82,906
JanuviaSitagliptin Phosphate56$57,533
JardianceEmpagliflozin61$45,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$43,907
LinzessLinaclotide49$35,848
EliquisApixaban29$33,019
RybelsusSemaglutide19$30,893
VraylarCariprazine Hcl19$27,264
WegovySemaglutide12$21,251
XareltoRivaroxaban15$19,255
MyrbetriqMirabegron32$14,946
Tresiba Flextouch U-200Insulin Degludec26$14,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,164$274,568239 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,401$190,906245 claims
Novo NordiskOzempic, Rybelsus, Wegovy$1,874$135,050107 claims
MerckJanuvia, Janumet$566$68,30668 claims
AbbVieLinzess, Vraylar$1,932$63,11268 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$503$51,95167 claims
Boehringer IngelheimJardiance$444$45,89161 claims
PfizerEliquis, Abrysvo$660$41,90358 claims
Johnson & JohnsonXarelto$85$19,25515 claims
Astellas Pharma US IncMyrbetriq$147$14,94632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →